Biosign announces UFIT health monitoring study

TORONTO, May 12 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign) announced today the initiation of a short-term study of the UFIT® biomedical system to determine the "best practices" for monitoring blood pressure and blood glucose. The study is being conducted in collaboration with McMaster University, which will use Biosign's technology to benchmark a technology framework for providing reliable and secure health information services.

To meet certain regulatory and market requirements, the study ("GAMUT-11") will involve several sites in various territories, including Europe, Canada, USA, and China. The precision and accuracy of UFIT® measurements will be further established, along with the reliability and validity of monitoring, all in conformity with internationally recognized standards. This additional UFIT® performance data shall augment the existing data from the successful completion of previous studies, including the year-long study conducted on diabetic amputees by Algogene Pain Genetics in collaboration with The University of Toronto Centre and The Centre for International Health.

"Biosign currently anticipates that the GAMUT study will be completed by the end of 2011", stated Dr. Radu Leca, Biosign's Founder and CEO. "Once we have completed this study, Biosign will be able to finalize our UFIT regulatory filing strategy and related timing for the United States and several other key markets."

UFIT® is Biosign's online system for recording and processing arterial blood pressure signals, which are captured at the wrist through an inflatable cuff. The system supports several medical measurements and applications for monitoring common health conditions. The blood pressure monitoring application (UFIT® TEN-10) has market clearances in Canada and Europe. The application for blood pressure and blood glucose monitoring (UFIT® TEN-20) has market clearance in Europe. As an online device for the non-invasive measurement of blood pressure and glucose, UFIT® TEN-20 should greatly simplify the way hypertension and diabetes are evaluated and managed.

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT® medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE Biosign Technologies Inc.

For further information:


Biosign Contact Information
 
Colley Clarke
Biosign Technologies
Phone: (416) 218-9800 ext. 234
Email: cfo@biosign.com
Alan S. Roemer
The Trout Group
Phone: (646) 378-2945
Email: aroemer@troutgroup.com

 

Profil de l'entreprise

Biosign Technologies Inc.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.